Clinical Trial Update: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3 [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating sofosbuvir (PSI-7977) plus ribavirin, with or without pegylated interferon, in treatment-naïve hepatitis C patients with gen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Hepatitis C Infection | Phase 2 | Status: COMPLETED | Results posted: 2014-11-17